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Background: Several studies show that psychological treatments relieve symptoms for patients suffering from irritable
bowel syndrome (IBS). However, there are no consistent findings that show what patient characteristics make a
psychological treatment more or less likely to result in improvement. We have previously conducted a study of a newly
developed internet-delivered cognitive behavioral therapy (ICBT) that emphasized exposure to IBS symptoms
and IBS-related situations and reduced symptom-related avoidance. The study showed that the treatment led to
improvement in IBS symptoms compared to a waiting list and that treatment gains were maintained over a
15–18 month follow-up period. The aim of the present study was to investigate several possible predictors of
short- and long-term treatment outcome in terms of symptom improvement, based on data collected in the
previously conducted treatment trial.
Methods: Demographics, comorbid psychological distress, IBS-related fear and avoidance behaviors, and
IBS-related disability were investigated as predictors of treatment outcome in the sample consisting of 79
participants diagnosed with IBS who had undergone 10 weeks of ICBT. Predictors that were significantly
correlated with symptom levels at post-treatment and follow-up were entered into multiple regression analyses
that controlled for pre-treatment symptom levels.
Results: There were measures within each domain, i.e., comorbid psychological distress, IBS-related fear and
avoidance behaviors, and IBS-related disability, with the exception of demographic data, that were correlated
with the symptom levels at post-treatment and follow-up. However, when these were entered into a multiple
regression analyses that controlled for pre-treatment levels, none remained a significant predictor of the
post-treatment and follow-up symptomatic status.
Conclusions: The study did not find any individual characteristics that made patients more or less likely to
respond to the exposure-based ICBT. The finding that comorbid psychological distress did not predict outcome
is in accordance with previous studies. Reliable predictors for response to any type of psychological treatment
for IBS remain to be established.
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Irritable bowel syndrome (IBS) affects about 11% of the
population [1], is characterized by recurring abdominal
pain and diarrhea and/or constipation [2] and associated
with decreased quality of life [3] and increased health-care
consumption [4]. Several different types of psychological
treatments have been studied as interventions for IBS, in-
cluding cognitive behavior therapy (CBT), psychodynamic
therapy, and hypnotherapy [5]. These treatments generally
show beneficial effects but treatment effects vary consider-
ably between studies of the same treatment types [6], and
little is known about what patient characteristics predict
successful outcome from psychological treatment. More
knowledge in this regard is important as it can contribute
to a better matching of patients to treatments and could
ultimately be used to increase the total proportion of par-
ticipants who respond to treatment [7].
The observation that many patients with IBS present
with comorbid psychiatric conditions or psychological dis-
tress [8], which are associated with increased symptom se-
verity [9], is often used as rationale for the application of
psychological treatments for IBS [6]. Based on this ration-
ale for psychological treatment, it would be reasonable to
assume that presence of psychiatric comorbidity or high
psychological distress would imply suitability, i.e., better
treatment response, for psychological interventions. How-
ever, results from prediction analyses have been contra-
dictory. We have found four studies that reported a
positive association between psychological distress at pre-
treatment and post-treatment improvement [10-13]. Eight
studies have reported the reverse association, i.e., that
psychological distress predicted worse outcome [14-21].
Finally, three studies reported no association between psy-
chological distress and outcome [22-24]. The measures of
psychological distress and the predicted outcome have dif-
fered between studies (not all have used symptomatic im-
provement as outcome), and the studies may therefore not
be completely comparable. Notwithstanding the different
methods, there does not seem to be much data backing up
the common proposition that patients with IBS should
benefit from psychological treatments just because they
display psychological distress e.g., [5].
However, although most psychological treatments for
IBS, in accordance with the common rationale, target co-
morbid psychological distress [6], there are also cognitive
behavioral treatments that target disorder-specific behav-
ioral patterns in IBS. During the last decade, several studies
of CBT based on behavioral exposure have been conducted
where the primary target of treatment has been IBS-related
avoidance and worry rather than comorbid psychological
distress [25-30]. This behavioral pattern, often referred to
as gastrointestinal symptom-specific anxiety (GSA) [31], is
associated with increased symptom severity and decreased
quality of life [32,33]. The exposure-based treatments haveconsistently produced large and stable effect sizes on mea-
sures of IBS symptoms and quality of life [25-30]. Thus,
the treatments that target GSA seem to be an exception
from the rule that psychological treatments for IBS show
large between-study variation in treatment effects. Based
on the model employed in these treatments targeting GSA,
it would be reasonable to assume that patients with IBS
who show high levels of GSA, more specifically IBS-related
avoidance behaviors, worry about IBS symptoms, and dis-
ability related to IBS, could be suitable candidates for treat-
ments targeting this symptom-specific pattern. We are
only aware of one study that has investigated the predictive
value of GSA and disability on outcome after an exposure-
based treatment. This study included a consecutively re-
cruited sample of clinical patients with IBS and did not
find that high pre-treatment levels of GSA and disability
were related to larger improvement in IBS symptoms after
an internet-delivered cognitive behavioral treatment
(ICBT) based on exposure exercises [25]. However, these
analyses were based on a small sample with a large propor-
tion of missing data, as 7 of 30 (23%) participants in the
treatment arm did not complete the post-treatment data,
limiting the statistical power to detect meaningful associa-
tions and possibly introducing bias in the prediction ana-
lyses. Another previous trial of ICBT for IBS [27], had less
missing data and several possible predictors were measured
before treatment, including psychiatric comorbidity, GSA,
and disability. Furthermore, the entire sample was assessed
at a long-term follow-up [34], allowing for prediction of
both the short- and long-term treatment effects. The
present predictor study is based on data from that trial.
The aim of the present study was to investigate the role
of psychological distress, GSA and IBS-related disability as
predictors of short- and long-term symptomatic improve-
ment following treatment with ICBT for IBS. Based on the
inconsistent findings in the IBS research on outcome pre-
diction we did not formulate any specific hypotheses.
Methods
Design
This study included 79 self-referred participants with a
diagnosis of IBS who had participated in a randomized
controlled study (ClinicalTrials.gov: NCT01171053) of
ICBT for IBS, where they were randomized to either treat-
ment (n = 39) or waiting list control (n = 40) for 10 weeks
([27]. After the 10-week post-treatment assessment partic-
ipants on the waiting list were crossed over to receive
treatment and subsequently completed a post-treatment
assessment after 10 additional weeks. In addition, both
groups participated in a long-term follow-up assessment
[34]. Since both groups were followed up simultaneously,
the time between treatment completion and follow-up
assessment was 18 months for the treatment group and
15 months for the group who received treatment after
Ljótsson et al. BMC Gastroenterology 2013, 13:160 Page 3 of 9
http://www.biomedcentral.com/1471-230X/13/160having been on the waiting list. In the present study, the
two samples were pooled together to predict the symptom-
atic changes from pre-treatment to post-treatment and
from pre-treatment to follow-up, based on pre-treatment
characteristics. This study was approved by the Regional
ethical review board in Stockholm (No: 2007/1451 - 31/4).
Participants
All participants had received a clinical diagnosis of IBS
before inclusion and fulfillment of Rome III criteria [2]
was confirmed before inclusion. Inclusion criteria, re-
cruitment procedure and participant characteristics are
detailed in the original report [27]. Because 6 of 85 par-
ticipants in the original trial withdrew from the study
before the post-treatment assessment, this study in-
cluded the remaining 79 (93%) who had participated in
the post-treatment (n = 76) and/or the follow-up assess-
ment (n = 74), and thus provided improvement data for
analysis in the present study. Sample characteristics are
presented in Table 1.Table 1 Pre-treatment characteristics and correlations with ou
n m
Outcome variables
GSRS-IBS at post-treatment 35.18




Duration of IBS 13.70
University studies (yes/no) 52/27
Predictor variables
GSRS-IBS at pre-treatment 47.74
Study group (treatment/waiting list) 39/40
Any anxiety disorder (yes/no) 39/40










*p < .05 for bivariate correlation between predictor and predicted GSRS-IBS score. G
Montgomery Åsberg Depression Rating Scale - Self Report, SSP-STA Swedish Univer
Universites Scales of Personalities – Psychic Trait Anxiety subscale, SCL-SOM Sympto
Sensitivity Index, CSQ-CAT Coping Strategies Questionnaire – Catastrophizing subsc
Disability Scales.Measures
All self-report measurements in the study were completed
online. Online assessment is considered a well-validated
form of administration of self-assessments and has been
shown to produce results similar to pen-and-paper admin-
istration [35].
Outcome
The Gastrointestinal Symptom Rating Scale –IBS version
(GSRS-IBS) [36] was used as the outcome measure in this
study. Because IBS symptoms vary considerably over time,
the GSRS-IBS was administered weekly during three
weeks at pre-treatment and post-treatment and four
weeks at follow-up. The weekly average score at each as-
sessment point was used to get reliable estimates of the
participants’ symptom levels.
Measures of psychological distress
During the inclusion procedure in the original study all






















SRS-IBS Gastrointestinal Symptom Rating Scale – IBS Version, MADRS-S
sites Scales of Personalities - Somatic Trait Anxiety subscale, SSP-STA Swedish
m Checklist – Somatization subscale, VSI Visceral Sensitivity Index, ASI Anxiety
ale, IBS-QOL Irritable Bowel Syndrome Quality of Life Instrument, SDS Sheehan
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(MINI) [37]. The MINI is a structured diagnostic inter-
view that identifies DSM-IV Axis-I disorders. The inter-
views were performed by advanced graduate students in
their final year of the Swedish psychology program and a
clinical psychologist. All interviewers were trained in
using the MINI and diagnosing psychiatric disorders.
The Montgomery Åsberg Depression Rating Scale - Self
report (MADRS-S) [38] was used to measure depressive
symptoms. The somatic trait anxiety (SSP-STA) and psy-
chic trait anxiety (SSP-PSTA) are two subscales of Swedish
Universities Scales of Personalities [39] and were used to
measure tendencies to feeling tense, restless, and worried.
To measure somatization, i.e., the tendency to experience
somatic symptoms in response to psychological distress, we
used the somatization subscale of the Symptom Checklist-
90 (SCL-SOM) [40]. The SCL-SOM measures the severity
of different somatic symptoms during the last week, e.g.,
headache, dizziness, pain, nausea, and weakness.
Measures of GSA and related constructs
The Visceral Sensitivity Index (VSI) [31], was used to
measure GSA, i.e., heightened anxiety and worry about
visceral sensation and IBS-associated situation (such as
not being near a toilet) and behavioral attempts to avoid
these stimuli. We used the catastrophizing subscale of
the Coping Strategies Questionnaire, which measures
the tendency to perceive pain sensation as catastrophic
and unbearable (CSQ-CAT) [41]. In the present study,
the participants were instructed to report their reactions
also to other IBS symptoms such as constipation, diar-
rhea, and bloating, in addition to pain. The Anxiety Sen-
sitivity Index (ASI) [42] was used to measure the degree
to which participants believed that symptoms of anxiety
and arousal could have negative consequences, such as
illness, embarrassment, or increased anxiety.
Measures of disability
The Irritable Bowel Syndrome Quality of Life Instrument
(IBS-QOL) [43] was used to assess the impact on quality
of life for patients with IBS in several domains, including
symptom interference with activity and impact on rela-
tionships. The Sheehan Disability Scales (SDS) [44] were
used to assess symptom induced disability in three do-
mains: social, work, and family.
Treatment
The treatment consisted of a 10-week ICBT-protocol based
on exposure and mindfulness exercises. Numerous studies
have demonstrated that cognitive behavioral treatments
for many somatic and psychiatric disorders can be delivered
over internet with effects similar to face-to-face treatment
[45]. The ICBT protocol in the present study was mainly
based on the principle of behavioral exposure, i.e.,participants provoked IBS symptoms and reduced their
avoidance of stimuli that induced symptoms or worry about
symptoms. The proposed mechanism was that the expos-
ure exercises, aided by mindfulness exercises, would break
the cycle of symptom and disability maintenance that the
GSA behavioral pattern constitutes, leading to improve-
ment in symptoms and quality of life. The original report
contains a detailed description of the treatment program
and results [27].
Assessment
All self-assessments were collected before treatment start.
The GSRS-IBS was also completed at post-treatment and
15–18 months follow-up. The telephone interviews, SSP-
STA, and SSP-PSTA were administered at the screening
phase of the study, i.e. 1 week to 3 months before treat-
ment start for the original treatment group and about 3–
6 months before treatment start for the waiting list.
Analysis
All statistical analyses were performed using SPSS 21. The
two samples, one with participants who received ICBT
directly and the other comprising participants who re-
ceived ICBT after 10 weeks on waiting list, were pooled
into a single sample to increase statistical power. This was
deemed acceptable, as there were no statistically signifi-
cant differences between the groups on any of the demo-
graphics (age, sex, and duration of IBS), predictors, or
dependent variables, i.e., the post-treatment and follow-up
scores on the GSRS-IBS. The analyses were conducted in
two steps. First, the GSRS-IBS post-treatment and follow-
up scores were correlated with the demographic and pre-
dictor variables. Second, all demographic and predictor
variables that were significantly correlated with the post-
treatment or follow-up GSRS-IBS scores were entered into
two separate multiple linear regression models, using the
post-treatment and the follow-up GSRS-IBS scores as the
dependent variable. The GSRS-IBS pre-treatment score
was included in both regression models to adjust for initial
baseline level and account for reliability of the measure-
ment. This procedure often yields results equivalent to
using residualized change scores in the prediction of treat-
ment outcomes [46] and is superior to dichomotization
(such as median split) in terms of increased power and de-
creased risk of type-I errors [46,47]. We also examined the
impact of outliers and multicollinearity on the results. The
power of the analysis to detect a predictor variable with a
moderate effect sixe (f2 = .15 or higher) was 93% with
alpha-level set at .05.
Results
Descriptive statistics
Table 1 displays descriptive statistics of the demographic,
predictor, and outcome variables. As can be seen in
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at pre-treatment to 35.18 at post-treatment and 32.58 at
follow-up for the whole sample. According to the MINI
interview before randomization, 42 participants had diag-
nosable psychiatric condition, 15 participants were diag-
nosed with major depressive disorder and 39 participants
with an anxiety disorder (the most common were agora-
phobia, n = 21, generalized anxiety disorder, n = 18, social
anxiety disorder, n = 10, and panic disorder, n = 10).
Bivariate correlations
The bivariate correlations between the demographic/pre-
dictor variables and the outcome measures are displayed
in Table 1. The pre-treatment scores on the GSRS-IBS
were significantly correlated with both the post-treatment
and follow-up scores on the same measure. In addition,
the CSQ-CAT, ASI, IBS-QOL, and SDS were significantly
correlated with the post-treatment GSRS-IBS score and
the diagnosis of major depressive disorder as well as scores
on the MADRS-S, VSI, CSQ-CAT, IBS-QOL, and SDS
were significantly correlated with the follow-up GSRS-IBS
score. With the exception of IBS-QOL, all significant cor-
relations were positive. This means that more severe
symptoms or disability were correlated with worse out-
come on the GSRS-IBS. None of the demographic vari-
ables were related to outcome.
Regression analyses
All predictors that were significantly correlated with the
outcome were entered into multiple linear regressionTable 2 Regression models predicting GSRS-IBS scores at pos
Coeff CI- CI
Prediction of GSRS-IBS at post-treatment. R = .536. R2 = .287. p < .001
Intercept 10.66 −18.52 39
GSRS-IBS pre-treatment 0.51 0.19 0
CSQ-CAT −0.03 −0.58 0
ASI −0.01 −0.29 0
IBS-QOL −0.05 −31.64 21
SDS 0.27 −0.23 0
Prediction of GSRS-IBS at follow-up. R = .441. R2 = .195. p = .039
Intercept 12.75 −25.75 51
GSRS-IBS pre-treatment 0.21 −0.12 0
Major depressive disorder 5.31 −2.32 12
MADRS-S 0.32 −0.15 0
VSI 0.08 −0.22 0
CSQ-CAT −0.01 −0.59 0
IBS-QOL 0.03 −30.83 36
SDS 0.04 −0.46 0
CI-: 95% Confidence interval, lower bound. CI + 95% Confidence Interval, upper bou
Montgomery Åsberg Depression Rating Scale - Self Report, VSI Visceral Sensitivity In
Catastrophizing subscale, IBS-QOL Irritable Bowel Syndrome Quality of Life Instrumeanalyses, separate for the post-treatment and follow-up
scores of the GSRS-IBS. The results of the regression
analyses are presented in Table 2. None of the predictor
variables remained significantly associated with the
post-treatment or follow-up scores on the GSRS-IBS,
with the exception of the pre-treatment GSRS-IBS score,
which significantly predicted the post-treatment GSRS-IBS
score. The models accounted for 28.7% (F(5,70) = 5.64,
p< .001) and 19.5% (F(7,66) = 2.28, p = .039) of the
variances in GSRS-IBS post-treatment and follow-up
scores, respectively.
Several alternative models were evaluated in sensitiv-
ity analyses. (1) When testing for possible multicolli-
nearity, the GSRS-IBS and VSI scores were found to be
highly correlated, r = .84. Because the model predicting
follow-up scores included both these measures, alterna-
tive models were tested with either the VSI or IBS-
QOL removed. (2) One outlier who scored more than 3
standard deviations above the sample mean on the
GSRS-IBS at both post-treatment and follow-up was
identified, and all analyses were rerun without this out-
lier. (3) The analyses were also rerun separately for the
original study’s treatment group and waiting list group.
(4) Each of the predictors that showed a significant bi-
variate correlation with the outcome measures were in-
vestigated separately by entering them into regression
models that only controlled for the pre-treatment
GSRS-IBS score (i.e., no other predictors were entered
into the model). None of these alternative models gave
substantially different results.t-treatment and follow-up
+ β t p Partial r
.84 0.73 .469
.83 .40 3.18 .002 .36
.51 -.02 −0.10 .921 -.01
.27 -.01 −0.08 .939 -.01
.48 -.08 −0.38 .704 -.05
.75 .16 1.08 .284 .13
.26 0.66 .511
.54 .18 1.25 .215 .15
.94 .17 1.39 .169 .17
.78 .20 1.37 .177 .17
.38 .11 0.53 .597 .07
.58 .00 −0.02 .985 .00
.68 .05 0.17 .863 .02
.54 .03 0.17 .866 .02
nd. GSRS-IBS Gastrointestinal Symptom Rating Scale, IBS version, MADRS-S
dex, ASI Anxiety Sensitivity Index, CSQ-CAT Coping Strategies Questionnaire –
nt, SDS Sheehan Disability Scales.
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In this study, we aimed to investigate possible predictors
of symptomatic improvement in a previously conducted
trial in which study participants with IBS underwent ICBT,
which targeted GSA by exposure exercises and mindful-
ness training. The investigated predictor domains were
psychological distress, GSA, and disability. The original re-
ports showed that the ICBT was effective in reducing IBS
symptoms and that improvements were maintained over a
long follow-up time [27,34]. Although several of the prog-
nostic factors were correlated with the symptomatic out-
come, none remained a significant predictor when entered
into a multiple regression model that included the pre-
treatment symptom levels. Thus, the results in this study
largely follow the same pattern of previous prediction
studies in the IBS field, with no variable appearing as a
clear and consistent predictor of treatment outcome. This
is important information from a clinical perspective as it
means that the clinician could, considering that ICBT
leads to symptom reduction, offer the treatment regardless
if the patient is an older woman with comorbid anxiety
and severe IBS symptoms or a younger man without psy-
chiatric comorbidity and moderate IBS symptoms.
Because the treatment under investigation in this study
did not target comorbid psychological distress, we did not
expect the presence of comorbid psychological distress to
be predictive of treatment success. However, it is interest-
ing to note that the proposed maintaining mechanisms of
the psychiatric disorders found in this sample (primarily
depression, panic disorder, social anxiety disorder, and
generalized anxiety disorder) are similar to how GSA
has been suggested to maintain IBS. Cognitive behavioral
models emphasize how threat-orientation, worry, and
avoidance related to disorder-specific stimuli serve to
maintain these disorders e.g., [48]. Given the high comor-
bidity between common psychiatric disorders, this behav-
ioral pattern has been suggested to be a shared causal
factor between many psychiatric disorders, labeled emo-
tional or experiential avoidance [49]. Similarly, there is a
large overlap between IBS and other functional somatic
disorders, e.g., fibromyalgia, chronic pain, and chronic fa-
tigue syndrome [8], and worry, fear, hypervigilance, and
avoidance in response to the disorder-specific symptoms
have also been suggested to be important maintaining
factors in these disorders as well as IBS [50]. Thus, emo-
tional or experiential avoidance seems to be a behavioral
phenomenon that unifies these functional somatic and
psychiatric disorders and GSA may simply be a manifest-
ation of this behavioral pattern in the context of IBS.
Therefore, a patient who presents with both depression
and IBS could be said not to be suffering from two comor-
bid disorders, of which one is especially suitable for psy-
chological treatment, but rather to be displaying an
avoidant behavioral pattern in response both to bowelsymptoms and the routine demands of life, while a patient
with IBS but without psychiatric comorbidity only displays
this behavioral pattern in response to bowel symptoms. In
essence, this putative explanation of the psychiatric co-
morbidity between the IBS and psychiatric disorders does
not stipulate that psychiatric disorders should be present
or absent for a GSA-focused treatment to work for IBS.
We have recently demonstrated that change on the VSI
is a mediator of treatment effect on IBS symptoms in the
exposure-based treatment for IBS [6]. This finding is in line
with the proposed role of GSA as a maintaining factor in
IBS and it could therefore be expected that patients who
score high on the VSI would benefit more from the treat-
ment than patients with low VSI scores. However, we did
not find that pre-treatment scores on the VSI predicted
symptomatic improvement. The stable placebo response in
IBS may be a possible explanation for this finding. Reviews
have shown that about 40% of patients with IBS respond to
placebo treatments [51]. It could be hypothesized that even
if participants with high levels of GSA, as measured by the
VSI, responded favorably to the exposure exercises, partici-
pants with lower levels of GSA could also show treatment
response, but this response would be due to unspecific fac-
tors rather than the specific interventions in the treatment.
Even if the placebo-induced treatment response among
low-GSA participants was smaller than the intervention-
specific response for high-GSA participants, these two
“competing” mechanisms of treatment response would
mean reduced power to detect the influence of pre-
treatment GSA levels on symptomatic reduction.
This reasoning is partly supported by our recent study
of mechanisms of change. There we observed that in the
exposure treatment, engagement in exposure and mind-
fulness exercises was associated with improvement on
the VSI (which in turn was associated with improvement
on the GSRS-IBS) but in the comparison arm, a stress
management condition, engagement in strategies such as
relaxation and lifestyle changes was not associated with
change in any measured mechanism [6]. Thus, the effect
in the stress management arm may have been due to
non-specific factors rather than specific symptom main-
taining factors in IBS. Also, it is important to underscore
that it is not necessary for GSA to predict outcome even
if it mediates the treatment effect. It could be that redu-
cing GSA leads to decreased symptoms, but that partici-
pants make similar GSA reductions, regardless of initial
baseline levels of GSA. If this was the case, than there
would be no strong predictive effect of GSA on outcome
as assessed in the present study.
There were some important limitations that need to
be considered when interpreting the results from this
study. First, this was a secondary analysis on data from a
study that was not designed to address the questions
posed in this article. The lack of predictive value of the
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all participants were self-referred and therefore prepared
to engage in a psychological treatment. A larger and more
representative sample could have presented with a larger
variation in pre-treatment characteristics and outcome
and thus revealed true differences between low and high
scoring groups that were not detectable in the sample
under investigation. Second, a larger sample could also
have provided more power to detect meaningful effects of
the pre-treatment characteristics on the GSRS-IBS at
post-treatment and follow-up. For example, the difference
between depressed and non-depressed participants on the
GSRS-IBS follow-up score was 5.31 with a 95% confidence
interval of −2.32 to 12.94 (p = .169), controlling for all
other predictors. As the follow-up score on the GSRS-IBS
was 32.58, the non-significant difference of 5.31 points be-
tween depressed and non-depressed could actually repre-
sent a meaningful difference in outcome (especially when
considering that by convention, the GSRS-IBS is scored
between 13 and 91, rather than between 0 and 78, which
in essence means that all difference scores should be com-
pared with absolute scores subtracted with 13, i.e., a differ-
ence of 5.31 compared with a zero-based mean follow-up
score of 19.58). Third, most of the psychiatric assessments
were made by final year psychology students who assessed
the presence of psychiatric diagnosis in interviews con-
ducted over the telephone. The proportion of participants
with a psychiatric disorder in this study, 42 of 79 (53%), is
close to the common approximation that about half of the
IBS population has a diagnosable psychiatric disorder [52].
Still, with inexperienced assessors, individual participants
may have been misclassified, limiting the validity of the
prediction analyses based on the presence of psychiatric
diagnosis. Fourth, the VSI may not be a measure that ad-
equately captures the GSA phenomenon as it pertains to
the exposure-based treatment. Of the 13 items on the VSI,
only two measure behavioral responses to the IBS in terms
of avoidance and safety behaviors while the remaining 11
items measure symptom-related worry, preoccupation,
and sensitivity [31]. Because the exposure-based treatment
mainly targets excessive avoidance and control behaviors,
the VSI may not measure the behavioral aspects of GSA
that are most relevant for prediction of outcome of this
treatment. The Irritable Bowel Syndrome-Behavioral Re-
sponses Questionnaire (IBS-BRQ) [53], which only mea-
sures IBS-related avoidance and control behaviors, could
have proved to be a better measure of suitability for the
treatment. In fact, high scores on the IBS-BRQ have been
shown to predict better response to CBT for IBS [13]. How-
ever, that specific CBT protocol was not exposure-based
[54] and the predicted outcomes were work and social
adjustment and not symptomatic improvement. Therefore,
the results from the prediction study that included the IBS-
BRQ may not be comparable with this study.Given the results of this and previous prediction studies,
it is possible that the search for individual characteristics as
stable predictors of treatment outcome is futile. It is also
important to note that even if variation in specific individ-
ual characteristics were found to be associated with treat-
ment outcome, most likely they will be associated with an
increased likelihood that symptomatic improvement will
occur rather than be binary determinants of whether an in-
dividual participant will respond or not. An important
venue of future research could then be to focus on other
potential predictors of outcome related to the therapeutic
process rather than pre-treatment characteristics, for ex-
ample treatment expectancy, treatment adherence, and
treatment response patterns. The outcome of ICBT for
fibromyalgia, social anxiety disorder, severe health anxiety
disorder has been shown to be associated with the partici-
pants’ adherence to treatment [55-57] and early response
during the course of face-to-face CBT for IBS has been as-
sociated with better long-term improvement [58].
Conclusions
The findings of the present study suggest that ICBT for
IBS has similar effects on symptoms regardless of demo-
graphic characteristics and psychiatric comorbidity in a
self-referred sample. Considering the large prevalence of
IBS and the many different psychological treatment proto-
cols that have been developed, the need for more know-
ledge about how to match patients to treatment remains.
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